Gastrointestinal Neuroendocrine Tumors
Associated Genetic Biomarkers
NCI Definition: A well-differentiated neuroendocrine tumor arising from the digestive system. It is characterized by the presence of cells with features similar to those of the normal endocrine cells of the digestive system. The neoplastic cells express immunohistochemical evidence of neuroendocrine differentiation and hormones. There is mild to moderate nuclear atypia and less than 20 mitoses per 10 HPF. It includes well-differentiated endocrine tumors or carcinoid tumors and well-differentiated endocrine carcinomas. 
Gastrointestinal neuroendocrine tumorss most frequently harbor alterations in TP53, MEN1, KRAS, CDKN2A, and ATM .
TP53 Mutation, TP53 c.217-c.1178 Missense, TP53 Missense, MEN1 Mutation, and ATM Mutation are the most common alterations in gastrointestinal neuroendocrine tumors .
There are 11 clinical trials for gastrointestinal neuroendocrine tumors, of which 10 are open and 1 is completed or closed. Of the trials that contain gastrointestinal neuroendocrine tumors as an inclusion criterion, 2 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), 5 are phase 2 (5 open), 1 is phase 3 (1 open), and 1 is no phase specified (0 open).
SSTR1, SSTR2, and SSTR3 are the most frequent gene inclusion criteria for gastrointestinal neuroendocrine tumors clinical trials .
Everolimus, lutetium lu 177-edotreotide, and svn53-67/m57-klh peptide vaccine are the most common interventions in gastrointestinal neuroendocrine tumors clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.